Table 2. Results with blinatumomab in... | American Society of Hematology

Table 2.

Results with blinatumomab in MRD-positive ALL

Author	Year	N	Population	MRD response	SCT rate (%)	Overall survival
Topp et al¹⁹ Gökbuget et al²⁰	2011	10	MRD > 0.01% Adult: 47 (20-77) y PCR	80%	45	Nr
Gökbuget et al^24,26	2018 2020	110	MRD > 0.1% First/later CR Adult: 45 (18-76) y PCR	88% 80% CR 83% CR1 73% CR2	67	Median 36 mo 43% at 5 y
Gökbuget et al²⁵	2020	64	MRD > 0.01% First CR Adult: 44 (18-83) y PCR	82% 67% CR	67	Median nr 64% at 2 y
Haddad et al²⁷	2021	31	MRD > 0.01% First/later CR Adult: 42 (22-84) y Ph-pos/neg Flow	74% CR 84% Ph-neg 62% Ph-pos	35	Median nr 63% at 3 y
Keating et al²⁸	2019	15	MRD > 0.01% Pediatric: 0-21 y Flow	14/15 MRD-neg	100^*	Median nr 93% 1 y
Locatelli et al²⁹	2020	12	MRD > 0.1% Pediatric PCR	92%	Nr	Nr
Locatelli et al³⁰	2021	29	MRD > 0.01% Ped R/R: 1-18 y Mainly PCR	93%	Nr	Nr
Bassan et al³¹	2021	23	MRD > 0.01% Adult: 18-65 y PCR	87%	Nr	Nr

Author	Year	N	Population	MRD response	SCT rate (%)	Overall survival
Topp et al¹⁹ Gökbuget et al²⁰	2011	10	MRD > 0.01% Adult: 47 (20-77) y PCR	80%	45	Nr
Gökbuget et al^24,26	2018 2020	110	MRD > 0.1% First/later CR Adult: 45 (18-76) y PCR	88% 80% CR 83% CR1 73% CR2	67	Median 36 mo 43% at 5 y
Gökbuget et al²⁵	2020	64	MRD > 0.01% First CR Adult: 44 (18-83) y PCR	82% 67% CR	67	Median nr 64% at 2 y
Haddad et al²⁷	2021	31	MRD > 0.01% First/later CR Adult: 42 (22-84) y Ph-pos/neg Flow	74% CR 84% Ph-neg 62% Ph-pos	35	Median nr 63% at 3 y
Keating et al²⁸	2019	15	MRD > 0.01% Pediatric: 0-21 y Flow	14/15 MRD-neg	100^*	Median nr 93% 1 y
Locatelli et al²⁹	2020	12	MRD > 0.1% Pediatric PCR	92%	Nr	Nr
Locatelli et al³⁰	2021	29	MRD > 0.01% Ped R/R: 1-18 y Mainly PCR	93%	Nr	Nr
Bassan et al³¹	2021	23	MRD > 0.01% Adult: 18-65 y PCR	87%	Nr	Nr

^*

Selected for SCT. Neg, negative; nr, not reported; pos, positive.